Summit Therapeutics Inc. 8-K

What Happened
Summit Therapeutics Inc. (SMMT) filed an 8-K on January 12, 2026 reporting a preliminary, unaudited cash, cash equivalents and short-term investments balance of approximately $710 million as of December 31, 2025. The company noted this amount is preliminary, subject to financial close procedures, and may differ materially from the final consolidated financial statements. On the same date, Summit presented at the 44th Annual J.P. Morgan Healthcare Conference; the investor presentation slides were furnished as Exhibit 99.1 to the filing.

Key Details

• Preliminary cash, cash equivalents and short-term investments: approximately $710 million (as of 12/31/2025).
• Filing date and presentation: January 12, 2026; presentation at the 44th Annual J.P. Morgan Healthcare Conference.
• Presentation and related materials filed as exhibits: Exhibit 99.1 (investor slides) plus press releases (Exhibits 99.2 and 99.3).
• Report signed by Manmeet S. Soni, Chief Operating Officer, Chief Financial Officer and Director (Principal Financial Officer).

Why It Matters
A roughly $710M preliminary cash and short-term investment balance indicates substantial liquidity that can support Summit’s operations and clinical or business activities in the near term. However, the figure is unaudited and preliminary — investors should wait for the completed year-end consolidated financial statements for final, audited numbers. The J.P. Morgan presentation may provide operational or program updates; review the furnished slides and press releases for additional context on corporate strategy, programs, or timing that could affect the company’s outlook.

Keywords: cash position, liquidity, earnings, quarterly results, CFO, investor presentation, J.P. Morgan.